Medical AI Alliance
Company Index
Pharma & CDMOKOSDAQ 074430

AMINOLOGICS CO.,LTD.

Official website

Aminologics supplies APIs for stroke and eye disease treatments plus amino-acid derivative intermediates like D-Serine to domestic pharma firms.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1997, Aminologics listed on KOSDAQ in 2004 as an API and amino acid derivative company. It supplies domestic finished-drug manufacturers with active pharmaceutical ingredients for stroke, eye disease, dermatitis, and cosmetics, while manufacturing and selling amino acid derivatives such as D-Serine, D-Alanine, D-Phenylalanine, and D-Arginine. D-Serine serves as an intermediate for the tuberculosis drug Cycloserine and the anticonvulsant Lacosamide, while D-Alanine is an intermediate for the prostate cancer drug Degarelix, and the company has launched a new amino acid derivative nearly every year from D-allo-Threonine in 2011 through Boc-His(Boc)-OH and others in 2024.

Products & technology

  • D-allo-ThreonineAPI starting material intermediate
  • D-SerineIntermediate for Cycloserine, Goserelin, Buserelin, Lacosamide, and others
  • D-allo-IleAPI starting material intermediate
  • D-AlanineIntermediate for Cetrorelix, Ganirelix, Pralmorelin, Abarelix, Degarelix, and others
  • D-PhenylalanineIntermediate for Octreotide, Nateglinide, Bivalirudin, Ubenimex, and others
  • D-CysteineIntermediate for Cefminox sodium, Romidepsin, and others
  • D-Naphthyl alanineIntermediate for Nafarelin, Lanreotide, Ganirelix, and others
  • D-ArginineIntermediate for Desmopressin, Velcalcetide, Icatibant, and others
  • Boc-D-Ser-OHIntermediate for Lacosamide, Goserelin, Buserelin, and others
  • HYP.OMe.HCl and othersIntermediate for Fosinopril, Doripenem, Meropenem, and others
  • Fmoc-D-Pro-OH and othersAPI starting material intermediate
  • 3-(2-Thienyl)-L-alanine and othersAPI starting material intermediate
  • Fmoc-D-Gln-OH and othersAPI starting material intermediate
  • Boc-His(Trt)-OH and othersAPI starting material intermediate
  • Fmoc-Asp(OAllyl)-OH and othersAPI starting material intermediate
  • Fmoc-7-Me-Trp-OH and othersAPI starting material intermediate
  • Fmoc-Trp(Me)-OH and othersAPI starting material intermediate
  • H-Gly-NH2.HCl and othersAPI starting material intermediate
  • Boc-His(Boc)-OH and othersAPI starting material intermediate
Not yet compiled: business overview · regulatory approvals · R&D. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

HL GENOMICS Co., Ltd.85
Kolmar BioTech, Inc.85

Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition